Biotech Firms Plan Global Investor Conferences

Surrozen will present at two upcoming healthcare investor conferences, with audio webcasts available for on-demand viewing. Ascentage Pharma is set to participate in four investor conferences, highlighting its pipeline including Olverembatinib as a first approved third‑generation BCR‑ABL1 inhibitor for certain CML indications and ongoing Phase III trials. Alpha Tau CFO will participate in September investor conferences to discuss Alpha DaRT, a targeted alpha-therapy for solid tumors. Nurix Therapeutics plans fireside chats at several investor events to outline its targeted protein degradation platform and collaborations with Roche, Gilead, and Sanofi. Processa Pharmaceuticals will attend two September investor conferences, led by Sheila Gujrathi, after acquiring Vidya Therapeutics and advancing VT-7208, its BTK inhibitor, across multiple indications.